Welcome to our dedicated page for Sharp Therapeutics news (Ticker: SHRXF), a resource for investors and traders seeking the latest updates and insights on Sharp Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sharp Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sharp Therapeutics's position in the market.
Sharp Therapeutics (OTCQB: SHRXF) will present preclinical data for its lead, Phase 1–ready small‑molecule ‘901 program targeting Gaucher disease and GBA Parkinson's disease at the World Orphan Drug Congress 2025 in Amsterdam on Oct 27–29, 2025. The company will present on Oct 27 at 2:45 p.m. CET and will review its clinical targets and pipeline, including programs for Niemann‑Pick disease type C and familial frontotemporal dementia. Sharp describes ‘901 as an oral candidate designed to restore lysosomal enzyme function with potential to treat peripheral and CNS manifestations and notes plans to initiate clinical studies in the near term.
Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) has announced its Q2 2025 financial results and its listing on the OTCQB market. The company reported an 85% increase in R&D spending compared to Q2 2024, primarily focused on their Gaucher and Progranulin programs.
The pre-clinical stage company, which develops small-molecule therapeutics for genetic diseases, has expanded its market presence through the OTCQB listing and has applied for DTC eligibility to enhance trading accessibility. Sharp is progressing toward Phase I clinical trials planned for 2026, utilizing its discovery platform that combines high-throughput screening technologies with computationally optimized compound libraries.
FAQ
What is the current stock price of Sharp Therapeutics (SHRXF)?
